Optimizing tumor targeting of the lipophilic EGFR-binding radiotracer SKI 243 using a liposomal nanoparticle delivery system

Journal of Controlled Release

Volumn 149, Issue 3, 2011, Pages 292-298

  Medina, Oula Penate ^a   Pillarsetty, Nagavarakishore ^a   Glekas, Athanasios ^a   Punzalan, Blesida ^a   Longo, Valerie ^a   Gönen, Mithat ^a   Zanzonico, Pat ^a   Smith Jones, Peter ^a   Larson, Steven M ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Cancer; Diagnostics; Drug delivery; EGFR; Imaging; Inhibitors; Nanoparticle; Radio tracer; Theraphy

Indexed keywords

CANCER; DIAGNOSTICS; EGFR; IMAGING; INHIBITORS; THERAPHY;

BLOOD; DISEASES; DRUG DELIVERY; ENZYMES; LIPOSOMES; MEDICAL IMAGING; NANOPARTICLES; PHARMACOKINETICS; PHOSPHOLIPIDS; POSITRON EMISSION TOMOGRAPHY; RADIOACTIVE TRACERS;

TUMORS;

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEFITINIB; INDIUM 111; LIPOSOME; NANOPARTICLE; SKI 243 I 124; SKI 243 I 131; TRACER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CIRCULATION TIME; CONTROLLED STUDY; DRUG BINDING; DRUG TARGETING; HUMAN; HUMAN CELL; LIPID SOLUBILITY; LIPOPHILICITY; LIPOSOMAL DELIVERY; MALE; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; HUMANS; LIPOSOMES; MICE; MICE, NUDE; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 79951944772     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2010.10.024     Document Type: Article

References (27)

1. E. Mishani, A. Hagooly, Strategies for molecular imaging of epidermal growth factor receptor tyrosine kinase in cancer. J. Nucl. Med. 50 (8) (2009) 1199-1202.
2. V. Tolmachev, M. Friedman, M. Sandström, T. Eriksson, D. Rosik, M. Hodik, S. Ståhl, F. Frejd, A. Orlova, Affibody molecules for epidermal growth factor receptor targeting in vivo: aspects of dimerization and labeling chemistry, J. Nucl. Med. 50 (2009) 274-283.
3. J.G. Gelovani, Molecular imaging of epidermal growth factor receptor expression-activity at the kinase level in tumors with positron emission tomography, Cancer Metastasis Rev. 27 (4) (2008) 645-653.
4. E. Mishani, G. Abourbeh, Y. Rozen, O. Jacobson, D. Laky, I. Ben David, A. Levitzki, M. Shaul, Novel carbon-11 labeled 4-dimethyl-amino-but-2-enoic acid [4-(phenylamino)-quinazoline-6-yl]-amides: potential PET bioprobes for molecular imaging of EGFR-positive tumors, Nucl. Med. Biol. 31 (4) (2004) 469-476.
5. 6-IPQA - a novel PET radiotracer for imaging EGFR expression-activity in lung carcinomas, Mol. Imaging Biol. (2010 Sep 22).
6. A. Pal, A. Glekas, M. Doubrovin, J. Balatoni, M. Namavari, T. Beresten, D. Maxwell, S. Soghomonyan, S.A. Shavrin, L. Ageyeva, R. Finn, S.M. Larson, W. Bornmann, J.G. Gelovani, Molecular imaging of EGFR kinase activity in tumors with I-124-labeled small molecular tracer and positron emission tomography, Mol. Imaging Biol. 8 (5) (2006) 262-277.
7. J. Gelovani, Molecular imaging of epidermal growth factor receptor expression-activity at the kinase level in tumors with positron emission tomography, Cancer Metastasis Rev. 27 (4) (2008) 645-653.
8. 18F]-PEG group on tracer qualification of [4-(phenylamino)-quinazoline-6-YL]-amide moiety - an EGFR putative irreversible inhibitor, Appl. Radiat. Isot. 65 (10) (2007) 1140-1151.
9. G. Abourbeh, S. Dissoki Test, Evaluation of radiolabeled ML04, a putative irreversible inhibitor of epidermal growth factor receptor, as a bioprobe for PET imaging of EGFR-overexpressing tumors, Nucl. Med. Biol. 34 (1) (2007) 55-70.
10. K. Yokogawa, E. Nakashima, J. Ishizaki, H. Maeda, T. Nagano, F. Ichimura, Relationships in the structure-tissue distribution of basic drugs in the rabbit, Pharm. Res. 7 (7) (1990) 691-696.
11. V.P. Torchilin, Targeted pharmaceutical nanocarriers for cancer therapy and imaging, AAPS J. 9 (2) (2007) E128-E147.
12. F. Pastorino, C. Brignole, D. Marimpietri, P. Sapra, E.H. Moase, T.M. Allen, M. Ponzoni, Doxorubicin-loaded Fab' fragments of anti-disialoganglioside immunoliposomes selectively inhibit the growth and dissemination of human neuroblastoma in nude mice, Cancer Res. 63 (1) (2003) 86-92. (Pubitemid 36070424)
13. T.M. Allen, D.R. Mumbengegwi, G.J. Charrois, Anti-CD19-targeted liposomal doxorubicin improves the therapeutic efficacy in murine B-cell lymphoma and ameliorates the toxicity of liposomes with varying drug release rates, Clin. Cancer Res. 11 (9) (2005) 3567-3573.
14. L858R non-small-cell lung cancer cell line H3255, Cancer Res. 64 (20) (2004) 7241-7244.
15. P. Laakkonen, K. Vuorinen, Homing peptides as targeted delivery vehicles, Integr. Biol. 2 (2010) 326-337.
16. O. Penate Medina, T. Söderlund, L.J. Laakkonen, E.K. Tuominen, E. Koivunen, P.K. Kinnunen, Binding of novel peptide inhibitors of type IV collagenases to phospholipid membranes and use in liposome targeting to tumor cells in vitro, Cancer Res. 61 (10) (2001) 3978-3985. (Pubitemid 32720960)
17. H. Brockman, Lipid monolayers: why use half a membrane to characterize protein-membrane interactions? Curr. Opin. Struct. Biol. 9 (4) (1999) 425-427.
18. O. Penate Medina, Y. Zhu, K. Kairemo, Targeted liposomal drug delivery in cancer, Curr. Pharm. Des. 10 (24) (2004) 2981-2989. (Pubitemid 39214006)
19. F. Pastorino, C. Brignole, D. Di Paolo, B. Nico, A. Pezzolo, D. Marimpietri, G. Pagnan, F. Piccardi, M. Cilli, R. Longhi, D. Ribatti, A. Corti, T.M. Allen, M. Ponzoni, Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy, Cancer Res. 66 (20) (2006) 10073-10082. (Pubitemid 44672061)
20. O. Penate Medina, K. Kairemo, H. Valtanen, A. Kangasniemi, S. Kaukinen, I. Ahonen, P. Permi, A. Annila, M. Sneck, J.M. Holopainen, S.L. Karonen, P.K. Kinnunen, E. Koivunen, Radionuclide imaging of tumor xenografts in mice using a gelatinase-targeting peptide, Anticancer Res. 25 (1A) (2005) 33-42. (Pubitemid 40470088)
21. G.S. van Bochove, L.E. Paulis, D. Segers, W.J. Mulder, R. Krams, K. Nicolay, G.J. Strijkers, Contrast enhancement by differently sized paramagnetic MRI contrast agents in mice with two phenotypes of atherosclerotic plaque, Contrast Media Mol. Imaging (2010 Sep 29)8 [Epub ahead of print].
22. T. Lammers, F. Kiessling, W. Hennink, G. Storm, Nanotheranostics and image-guided drug delivery: current concepts and future directions, Mol Pharm. 7 (6) (2010) 1899-1912. Epub 2010 Oct 6.
23. G.D. Kenny, N. Kamaly, T.L. Kalber, L.P. Brody,M. Sahuri, E. Shamsaei, A.D.Miller, J.D. Bell, Novel multifunctional nanoparticle mediates siRNA tumour delivery, visualisation and therapeutic tumour reduction in vivo, J. Control. Release (2010 Oct 1). [Epub ahead of print] PMID: 20888381 [PubMed - as supplied by publisher].
24. A. Levitzki, E. Mishani, Tyrphostins and other tyrosine kinase inhibitors, Annu. Rev. Biochem. 75 (2006) 93-109. (Pubitemid 44118027)
25. C. Le Tourneau, L. Vidal, L.L. Siu, Progress and challenges in the identification of biomarkers for EGFR and VEGFR targeting anticancer agents, Drug Resist. Updat. 11 (3) (2008) 99-109.
26. W. Cai, G. Niu, X. Chen, Multimodality imaging of the HER-kinase axis in cancer, Eur. J. Nucl. Med. Mol. Imaging 35 (1) (2008) 186-208. (Pubitemid 350234146)
27. Y. Rukazenkov, G. Spaeke, G. Marshall, J. Anderton, B.R. Davies, R.W. Wilkinson, D. Marck Hickinson, A. Swaisland, Epidermal growth factor receptor tyrosine kinase inhibitors: similar but different? Anticancer Drugs 20 (10) (2009) 856-866.